8-K filing — PDS Biotechnology Corp (PDSB)
Filed: 2026-09-22 AccNo: 0001140361-26-037298 Size: 173 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
PDS Biotechnology Announces Publication Of Results From Phase 2 Trial Evaluating PDS0101, HPV16-Targeted Immunotherapy, In Combination With Pembrolizumab In JAMA Oncology, Peer Reviewed Journal Of American Medical Association
39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patientsCompany continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy for
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
PDS Biotech Stock Surges Tuesday: What's Driving the Action?
Shares of PDS Biotechnology Corp (NASDAQ: PDSB) are trading sharply higher Tuesday afternoon, extending Monday's gains as investors continue to react to the closing of a multi-tranche financing agreement.
PDS Biotech shares are trading higher. The company announced initial closing of up to $22.3 million PIPE financing.